Laura Mezquita

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations

Life Sciences, Immunology, Oncology +17

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

Kathryn C. Arbour, Laura Mezquita, Niamh M. Long et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 951 citations · Full text

Life Sciences, Immunology, Oncology +17

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14